CA3180794A1 - Methods of treatment of tuberous sclerosis complex - Google Patents
Methods of treatment of tuberous sclerosis complex Download PDFInfo
- Publication number
- CA3180794A1 CA3180794A1 CA3180794A CA3180794A CA3180794A1 CA 3180794 A1 CA3180794 A1 CA 3180794A1 CA 3180794 A CA3180794 A CA 3180794A CA 3180794 A CA3180794 A CA 3180794A CA 3180794 A1 CA3180794 A1 CA 3180794A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035313P | 2020-06-05 | 2020-06-05 | |
| US63/035,313 | 2020-06-05 | ||
| PCT/EP2021/065075 WO2021245281A1 (en) | 2020-06-05 | 2021-06-04 | Methods of treatment of tuberous sclerosis complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180794A1 true CA3180794A1 (en) | 2021-12-09 |
Family
ID=76325558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180794A Pending CA3180794A1 (en) | 2020-06-05 | 2021-06-04 | Methods of treatment of tuberous sclerosis complex |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11684613B2 (enExample) |
| EP (1) | EP4161512A1 (enExample) |
| JP (2) | JP2023528895A (enExample) |
| KR (2) | KR20230027145A (enExample) |
| CN (1) | CN116056701A (enExample) |
| AU (1) | AU2021285273A1 (enExample) |
| BR (1) | BR112022024760A2 (enExample) |
| CA (1) | CA3180794A1 (enExample) |
| CL (1) | CL2022003435A1 (enExample) |
| IL (2) | IL322310A (enExample) |
| MX (1) | MX2022015407A (enExample) |
| PH (1) | PH12023550016A1 (enExample) |
| WO (1) | WO2021245281A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022015407A (es) * | 2020-06-05 | 2023-05-16 | Noema Pharma Ag | Metodos de tratamiento del complejo de esclerosis tuberosa. |
| CN120641098A (zh) * | 2023-02-02 | 2025-09-12 | 诺埃玛制药公司 | Dravet综合征的治疗方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508560A (en) | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
| CN100548299C (zh) | 2001-01-05 | 2009-10-14 | 伊莱利利公司 | 兴奋性氨基酸受体拮抗剂 |
| TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| HRP20080363T3 (hr) | 2004-06-01 | 2008-09-30 | F. Hoffmann - La Roche Ag | Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora |
| EP1756086B1 (en) | 2004-06-01 | 2008-06-04 | F.Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
| AU2007336369B2 (en) * | 2006-12-21 | 2013-01-17 | F. Hoffmann-La Roche Ag | Polymorphs of a mGluR5 receptor antagonist |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| JP2013505262A (ja) | 2009-09-17 | 2013-02-14 | バンダービルト ユニバーシティー | ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法 |
| US20120039999A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| CA2845578C (en) | 2011-08-25 | 2016-02-16 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| MX2022015407A (es) * | 2020-06-05 | 2023-05-16 | Noema Pharma Ag | Metodos de tratamiento del complejo de esclerosis tuberosa. |
| TWI924682B (zh) | 2020-07-30 | 2026-05-11 | 瑞士商諾埃瑪製藥公司 | 三叉神經痛之治療方法 |
| US20240285637A1 (en) | 2021-07-08 | 2024-08-29 | The Royal Institution For The Advancement Of Learning/Mcgill University | Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms |
| CN119677515A (zh) | 2022-06-15 | 2025-03-21 | 美国政府健康及人类服务部 | 使用代谢型谷氨酸受体5拮抗剂或/和大麻素受体1拮抗剂治疗纤维化疾病 |
| EP4584250A4 (en) | 2022-09-06 | 2026-02-25 | Biohaven Therapeutics Ltd | POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS |
| US20260124188A1 (en) | 2022-10-28 | 2026-05-07 | Orphelion Ab | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal |
| CN120641098A (zh) | 2023-02-02 | 2025-09-12 | 诺埃玛制药公司 | Dravet综合征的治疗方法 |
| EP4680203A1 (en) | 2023-03-14 | 2026-01-21 | Prolevi Bio AB | Compositions for sustained release of poorly soluble active ingredients |
-
2021
- 2021-06-04 MX MX2022015407A patent/MX2022015407A/es unknown
- 2021-06-04 BR BR112022024760A patent/BR112022024760A2/pt unknown
- 2021-06-04 KR KR1020237000370A patent/KR20230027145A/ko not_active Ceased
- 2021-06-04 CN CN202180057592.9A patent/CN116056701A/zh active Pending
- 2021-06-04 CA CA3180794A patent/CA3180794A1/en active Pending
- 2021-06-04 KR KR1020257024877A patent/KR20250116184A/ko active Pending
- 2021-06-04 JP JP2022574675A patent/JP2023528895A/ja active Pending
- 2021-06-04 IL IL322310A patent/IL322310A/en unknown
- 2021-06-04 WO PCT/EP2021/065075 patent/WO2021245281A1/en not_active Ceased
- 2021-06-04 PH PH1/2023/550016A patent/PH12023550016A1/en unknown
- 2021-06-04 EP EP21730918.6A patent/EP4161512A1/en active Pending
- 2021-06-04 AU AU2021285273A patent/AU2021285273A1/en active Pending
- 2021-06-04 IL IL298709A patent/IL298709A/en unknown
-
2022
- 2022-12-02 US US18/061,239 patent/US11684613B2/en active Active
- 2022-12-05 CL CL2022003435A patent/CL2022003435A1/es unknown
-
2023
- 2023-05-11 US US18/315,723 patent/US11998535B2/en active Active
-
2024
- 2024-04-22 US US18/641,640 patent/US12702661B2/en active Active
-
2025
- 2025-05-19 JP JP2025082998A patent/JP2025122066A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL322310A (en) | 2025-09-01 |
| CL2022003435A1 (es) | 2023-10-20 |
| US12702661B2 (en) | 2026-08-11 |
| PH12023550016A1 (en) | 2024-03-11 |
| KR20250116184A (ko) | 2025-07-31 |
| US20230100520A1 (en) | 2023-03-30 |
| US11998535B2 (en) | 2024-06-04 |
| IL298709A (en) | 2023-02-01 |
| JP2023528895A (ja) | 2023-07-06 |
| JP2025122066A (ja) | 2025-08-20 |
| BR112022024760A2 (pt) | 2023-03-07 |
| WO2021245281A1 (en) | 2021-12-09 |
| MX2022015407A (es) | 2023-05-16 |
| US20230277513A1 (en) | 2023-09-07 |
| EP4161512A1 (en) | 2023-04-12 |
| CN116056701A (zh) | 2023-05-02 |
| AU2021285273A1 (en) | 2023-01-19 |
| KR20230027145A (ko) | 2023-02-27 |
| US20250099445A1 (en) | 2025-03-27 |
| US11684613B2 (en) | 2023-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250099445A1 (en) | Methods of treatment of tuberous sclerosis complex | |
| AU2006256851B2 (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
| US20250345320A1 (en) | Methods of treatment of trigeminal neuralgia | |
| CN101896477B (zh) | 硝克柳胺化合物晶v型、其制法和其药物组合物与用途 | |
| EP4486337A1 (en) | Triple uptake inhibitor for the treatment of atypical depression | |
| OA21484A (en) | Methods of treatment of tuberous sclerosis complex. | |
| KR20250140536A (ko) | 드라베 증후군의 치료 방법 | |
| OA21124A (en) | Methods of treatment of trigeminal neuralgia. | |
| WO2025096684A1 (en) | Err modulators | |
| HK1140947B (en) | Pharmaceuticals compositions of a neuroactive steroid and uses thereof | |
| HK1118202B (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
| HK1145987A (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240802 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240802 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250603 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250603 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250603 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250605 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250606 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250818 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250818 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250818 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250818 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251211 |